X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x - 23.2 - View Chart
P/BV x 6.7 3.4 198.2% View Chart
Dividend Yield % 0.6 0.7 95.1%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUN PHARMA
Mar-17
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589842 188.7%   
Low Rs1,232572 215.2%   
Sales per share (Unadj.) Rs417.5131.6 317.2%  
Earnings per share (Unadj.) Rs56.332.7 172.1%  
Cash flow per share (Unadj.) Rs64.738.0 170.4%  
Dividends per share (Unadj.) Rs12.703.50 362.9%  
Dividend yield (eoy) %0.90.5 181.9%  
Book value per share (Unadj.) Rs292.9152.7 191.8%  
Shares outstanding (eoy) m119.572,399.26 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.4 62.9%   
Avg P/E ratio x25.121.6 115.9%  
P/CF ratio (eoy) x21.818.6 117.0%  
Price / Book Value ratio x4.84.6 104.0%  
Dividend payout %22.610.7 210.8%   
Avg Mkt Cap Rs m168,6531,696,877 9.9%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m9,17149,023 18.7%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m49,915315,784 15.8%  
Other income Rs m1,6456,232 26.4%   
Total revenues Rs m51,561322,016 16.0%   
Gross profit Rs m8,482100,893 8.4%  
Depreciation Rs m1,00612,648 8.0%   
Interest Rs m6713,998 16.8%   
Profit before tax Rs m8,45190,479 9.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60612,116 13.3%   
Profit after tax Rs m6,73178,462 8.6%  
Gross profit margin %17.031.9 53.2%  
Effective tax rate %19.013.4 141.9%   
Net profit margin %13.524.8 54.3%  
BALANCE SHEET DATA
Current assets Rs m27,062329,537 8.2%   
Current liabilities Rs m15,324178,870 8.6%   
Net working cap to sales %23.547.7 49.3%  
Current ratio x1.81.8 95.9%  
Inventory Days Days6779 84.2%  
Debtors Days Days4183 49.6%  
Net fixed assets Rs m12,610204,766 6.2%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m34,490363,997 9.5%   
Net worth Rs m35,027366,397 9.6%   
Long term debt Rs m1,21214,361 8.4%   
Total assets Rs m54,387614,102 8.9%  
Interest coverage x13.623.6 57.6%   
Debt to equity ratio x00 88.3%  
Sales to assets ratio x0.90.5 178.5%   
Return on assets %13.613.4 101.4%  
Return on equity %19.221.4 89.7%  
Return on capital %24.924.8 100.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56344,118 14.9%   
Fx outflow Rs m3,01224,484 12.3%   
Net fx Rs m3,55219,634 18.1%   
CASH FLOW
From Operations Rs m7,25970,822 10.2%  
From Investments Rs m1,864-42,216 -4.4%  
From Financial Activity Rs m-9,273-22,854 40.6%  
Net Cashflow Rs m-1506,107 -2.5%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Nov 20, 2017 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS